TAVLESSE

This brand name is authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Italy, Lithuania, Poland, Spain, UK.

Active ingredients

The drug TAVLESSE contains one active pharmaceutical ingredient (API):

1	Fostamatinib disodium hexahydrate UNII 86EEZ49YVB - FOSTAMATINIB DISODIUM
	Fostamatinib mediates its activity effectively through its major metabolite, R406, which is a tyrosine kinase inhibitor with demonstrated activity against spleen tyrosine kinase (SYK). R406 inhibits signal transduction of B-cell receptors and Fc-activating receptors, which play a key role in antibody-mediated cellular responses. The fostamatinib metabolite R406 reduces antibody-mediated destruction of platelets.
	Read more about Fostamatinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TAVLESSE Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B02BX09		B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BX Other systemic hemostatics
Discover more medicines within B02BX09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1809480, 1809491, 1809503, 1809514
ES	Centro de información online de medicamentos de la AEMPS	1191405001, 1191405002
FI	Lääkealan turvallisuus- ja kehittämiskeskus	132187, 192372
FR	Base de données publique des médicaments	62637153, 65212047
GB	Medicines & Healthcare Products Regulatory Agency	387056, 387058
IT	Agenzia del Farmaco	048441012, 048441024
LT	Valstybinė vaistų kontrolės tarnyba	1089186, 1089187
PL	Rejestru Produktów Leczniczych	100429958, 100429964